<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862859</url>
  </required_header>
  <id_info>
    <org_study_id>DANWARD 1.25</org_study_id>
    <secondary_id>2018-000484-86</secondary_id>
    <nct_id>NCT03862859</nct_id>
  </id_info>
  <brief_title>The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis</brief_title>
  <acronym>DANWARD</acronym>
  <official_title>The Danish Warfarin-Dialysis Study: Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis - A Nationwide Parallel-group Open Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Carlson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the appropriateness of initiating oral anticoagulation for stroke&#xD;
      risk reduction in dialysis populations with atrial fibrillation. Specifically, the study will&#xD;
      assess the overall safety, tolerability, and efficacy of initiating treatment with Warfarin&#xD;
      in patients with end-stage renal disease on dialysis and de novo atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data pertaining to the tolerability, safety, and benefit of initiating anticoagulation for&#xD;
      stroke risk reduction in patients with end-stage renal disease and atrial fibrillation&#xD;
      remains conflicting and insufficient. Patients on dialysis continue to be routinely excluded&#xD;
      from randomized controlled trials, and evidence from observational studies is plausibly&#xD;
      biased. The main objective of the following parallel-group open randomized clinical trial&#xD;
      presents a nationwide study aimed at investigating the benefit, tolerability, and safety of&#xD;
      initiating warfarin versus no treatment in patients with atrial fibrillation on dialysis. The&#xD;
      anticipated results from this project will provide conclusive evidence as to the&#xD;
      appropriateness of initiating oral anticoagulation for stroke risk reduction in dialysis&#xD;
      populations with atrial fibrillation with direct effects on clinical management and&#xD;
      international guidelines pertaining to these patients.&#xD;
&#xD;
      The study is planned as a multicentre, randomized, open label, parallel group trial with&#xD;
      planned inclusion of a total of 718 patients (359 patients per arm). Dialysis-treated&#xD;
      patients with end-stage renal disease with de novo or untreated prevalent diagnosis of&#xD;
      paroxysmal, persistent, or permanent atrial fibrillation will be enrolled and randomized to&#xD;
      either treatment with warfarin or no treatment. Randomization with be attained using a 1:1&#xD;
      allocation as per a computer-generated randomization schedule stratified by gender, age by&#xD;
      decade, and center using permuted blocks of random sizes. Study participants will be&#xD;
      allocated to treatment in accordance with the randomization for the full duration of the&#xD;
      trial i.e. at a minimum one year following randomization, and followed with regular&#xD;
      monitoring for the the primary efficacy outcome of ischemic stroke or death due to ischemic&#xD;
      or unspecified stroke and the primary safety outcome of major bleeding defined in accordance&#xD;
      with the International Society on Thrombosis and Hemostasis definition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentre, randomized, open label, parallel group study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy outcome - Number of participants with transient ischemic attack, fatal and non-fatal ischaemic or unspecific stroke</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Any transient ischemic attack, fatal and non-fatal ischaemic or unspecific stroke or death attributable to either ischemic or undefined stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety outcome - Number of participants with fatal or non-fatal major bleeding</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Any major bleeding as defined in accordance with the International Society on Thrombosis and Hemostasis definition pertaining to major bleeding in non-surgical patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ischemic or unspecified stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal ischemic stroke or unspecified stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ischemic stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal ischemic stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hemorrhagic stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal hemorrhagic stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ischemic or hemorrhagic stroke</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal ischemic or hemorrhagic stroke event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combination of any non-fatal stroke and all-cause mortality</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Number of participants with either non-fatal ischemic or hemorrhagic stroke of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The combination of any non-fatal stroke, any non-fatal major bleeding, and all-cause mortality</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Number of participants with either non-fatal ischemic or hemorrhagic stroke, any non-fatal major bleeding as defined in accordance with the International Society on Thrombosis and Hemostasis definition pertaining to major bleeding in non-surgical patients, or death due to any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Discontinuation of the allocated randomized therapy</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Number of participants discontinuing the allocated randomized therapy irrespective of cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with peripheral artery disease</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any diagnosis of previously unverified peripheral artery disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with fatal or non-fatal acute myocardial infarction</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Any non-fatal or fatal acute myocardial infarction event</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with calciphylaxis</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Development of calciphylaxis as defined by clinical diagnosis</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants hospitalized due to left-sided heart failure</measure>
    <time_frame>From time of randomization to end of observation - up to 4 years</time_frame>
    <description>Any hospitalization due to left-sided heart failure as defined by de novo LVEF &lt;30% with echocardiographic verification</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of participants with arteriovenous fistula thrombosis</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Arteriovenous fistula thrombosis in participants dialyzed via an arteriovenous fistula</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with osteoporotic fractures</measure>
    <time_frame>From randomization to end of observation - up to 4 years</time_frame>
    <description>Osteoporotic fractures as defined by low energy fractures of the proximal femur, distal radius, humerus, pelvis, and vertebrae</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">718</enrollment>
  <condition>Atrial Fibrillation and Flutter</condition>
  <condition>Stroke</condition>
  <condition>Major Bleed</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Treatment with Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin with dosing targeting an international normalized ratio of 2-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Dose adjusted Warfarin targeting an international normalized ratio of 2-3.</description>
    <arm_group_label>Treatment with Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>Marevan</other_name>
    <other_name>Jantoven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years on chronic dialysis due to end-stage renal disease with de novo&#xD;
             diagnosis of non-valvular paroxysmal, persistent, or permanent atrial fibrillation OR&#xD;
             non-treated (for &gt;2 months) prevalent paroxysmal, persistent or permanent atrial&#xD;
             fibrillation as documented by an electrocardiogram or an episode of ≥30 seconds on&#xD;
             Holter monitor, or episodes ≥ 6 minutes on event recorders or any other recording&#xD;
             device.&#xD;
&#xD;
          -  Competence to understand the study rationale, including potential risks and benefits&#xD;
             associated with treatment, necessary for written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHA2DS2-VASc Score ≤1&#xD;
&#xD;
          -  Other indications for oral anticoagulation treatment (pulmonary embolism &lt; 6 months,&#xD;
             deep vein thrombosis &lt;3 months, prior atrial fibrillation, mechanical heart valve&#xD;
             prosthesis) irrespective of whether treatment is implemented&#xD;
&#xD;
          -  Ongoing dual antiplatelet treatment&#xD;
&#xD;
          -  Malignancy (with exception of non-melanoma skin cancer) with recent &lt; 1 year, ongoing,&#xD;
             or planned curative, or palliative chemo- , radiation-, and/or scheduled surgical&#xD;
             therapy&#xD;
&#xD;
          -  Endoscopy with gastrointestinal ulcer &lt;1 month&#xD;
&#xD;
          -  Esophageal varices&#xD;
&#xD;
          -  Autoimmune og genetic coagulation disorders&#xD;
&#xD;
          -  Congenital alactasia, Lapp Lactase deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          -  Pending spinal tap&#xD;
&#xD;
          -  Cerebrovascular malformations&#xD;
&#xD;
          -  Arterial aneurysms&#xD;
&#xD;
          -  Ulcers or wounds (Wagner grad &gt;1)&#xD;
&#xD;
          -  Bacterial endocarditis &lt; 3 months&#xD;
&#xD;
          -  Active bleeding contraindicating anticoagulation&#xD;
&#xD;
          -  Any non-elective and/or non-ambulant surgery &lt;7 days&#xD;
&#xD;
          -  Cerebral hemorrhage &lt;4 weeks&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt;100 × 109/L) &lt;30 days.&#xD;
&#xD;
          -  Severe liver insufficiency (spontaneous international normalized ratio &gt;1.5) &lt;30 days.&#xD;
&#xD;
          -  Known intolerance to warfarin&#xD;
&#xD;
          -  Use of hypericum perforatum / St. John's Wort&#xD;
&#xD;
          -  Uncontrolled hypertension (repeat blood pressure &gt;180/110 mmhg) &lt; 30 days&#xD;
&#xD;
          -  Uncontrolled hyperthyroidism (thyroid-stimulating hormone &lt;0.1μIU/mL) &lt;30 days&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Participation in other ongoing intervention trials adjudged to influence study&#xD;
             outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Carlson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Copenhagen University Hospital Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar H Gislason, Prof MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danish Heart Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Lise Kamper, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology, Copenhagen University Hospital Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Carlson, MD PhD</last_name>
    <phone>+45 35455827</phone>
    <email>nicholas.carlson.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunnar H Gislason, Prof MD PhD</last_name>
    <phone>+45 70 25 00 00</phone>
    <email>Gunnar.Gislason@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hosptial</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper M Rantanen, MD PhD</last_name>
      <email>jemr@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian D Peters, MD PhD</last_name>
      <email>chipte@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Carlson, MD PhD</last_name>
      <phone>+45 35455927</phone>
      <email>nicholas.carlson.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Nicholas Carlson, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Lindhard Rasmussen, MD</last_name>
      <email>kristine.lindhard.rasmussen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Kristine Lindhard Rasmussen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of nephrology, Nordsjaellands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Bertelsen, MD</last_name>
      <email>marianne.camilla.bertelsen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Marianne Bertelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holbaek Hospital</name>
      <address>
        <city>Holbæk</city>
        <zip>4300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Lindhardt, MD PhD</last_name>
      <email>moli@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holstebro Hospital</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank H Mose, MD PhD</last_name>
      <email>frank.holden.christensen@vest.rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lillebælt Hospital</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donata Cibulskyte-Ninkovic, MD</last_name>
      <email>donata.cibulskyte-ninkovic@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikke Borg, MD PhD</last_name>
      <email>rbor@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Lene Boesby, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bornholms Hospital</name>
      <address>
        <city>Rønne</city>
        <zip>3700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Finn T Nielsen, MD</last_name>
      <email>finnthomsen.nielsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sønderjylland</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan D Kampmann, MD</last_name>
      <email>jdk@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Viborg Regional Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Tietze, MD PhD</last_name>
      <email>ida@tietze.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Nicholas Carlson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for primary and secondary outcomes measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 12 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed, requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

